Phase 3 testing confirms HIV fat disorder drug findings
(Montreal, Quebec) Theratechnologies has concluded a Phase 3 trial confirming earlier clinical results on the safety and effectiveness of its lead drug, tesamorelin, for an HIV-related fat disorder.
Patients lost 18 per cent of their excess visceral fat after 52 weeks of treatment, …
